n-oleoylethanolamine and Hypercholesterolemia

n-oleoylethanolamine has been researched along with Hypercholesterolemia* in 2 studies

Trials

1 trial(s) available for n-oleoylethanolamine and Hypercholesterolemia

ArticleYear
Modulation of plasma N-acylethanolamine levels and physiological parameters by dietary fatty acid composition in humans.
    Journal of lipid research, 2014, Volume: 55, Issue:12

    N-Acylethanolamines (NAEs) are endogenous lipid-signaling molecules involved in satiety and energetics; however, how diet impacts circulating NAE concentrations and their downstream metabolic actions in humans remains unknown. Objectives were to examine effects of diets enriched with high-oleic canola oil (HOCO) or HOCO blended with flaxseed oil (FXCO), compared with a Western diet (WD), on plasma NAE levels and the association with energy expenditure and substrate oxidation. Using a randomized controlled crossover design, 36 hypercholesterolemic participants consumed three isoenergetic diets for 28 days, each containing 36% energy from fat, of which 70% was HOCO, FXCO, or WD. Ultra-performance liquid chromatography-MS/MS was used to measure plasma NAE levels and indirect calorimetry to assess energy expenditure and substrate oxidation. After 28 days, compared with WD, plasma oleoylethanolamide (OEA) and alpha-linolenoyl ethanolamide (ALEA) levels were significantly increased in response to HOCO and FXCO (P = 0.002, P < 0.001), respectively. Correlation analysis demonstrated an inverse association between plasma OEA levels and percent body fat (r = -0.21, P = 0.04), and a positive association was observed between the plasma arachidonoyl ethanolamide (AEA)/OEA ratio and android:gynoid fat (r = 0.23, P = 0.02), respectively. Results suggest that plasma NAE levels are upregulated via their dietary lipid substrates and may modulate regional and total fat mass through lipid-signaling mechanisms.

    Topics: Adiposity; Adult; Body Mass Index; Cohort Studies; Cross-Over Studies; Dietary Fats; Endocannabinoids; Energy Metabolism; Fatty Acids, Monounsaturated; Female; Humans; Hypercholesterolemia; Linseed Oil; Male; Middle Aged; Oleic Acids; Overweight; Oxidation-Reduction; Patient Dropouts; Polyunsaturated Alkamides; Rapeseed Oil; Single-Blind Method; Up-Regulation

2014

Other Studies

1 other study(ies) available for n-oleoylethanolamine and Hypercholesterolemia

ArticleYear
Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis.
    Atherosclerosis, 2009, Volume: 205, Issue:2

    In this study we analysed the possible modulation of endocannabinoids and related molecules during atherosclerosis development in mice. Wild-type and apolipoprotein E knockout (ApoE(-/-)) mice were fed either normal chow or high-cholesterol diet for 8-12 weeks, and tissue endocannabinoid levels were measured by liquid chromatography-mass spectrometry. We found increased levels of 2-AG in aortas and visceral adipose tissue (VAT) of ApoE(-/-) mice fed on high-cholesterol diet for 12 weeks as compared to ApoE(-/-) mice fed on normal chow or wild-type mice fed on cholesterol. No significant difference in 2-AG levels was observed after 8 weeks of diet, and no changes in anandamide levels were found in any group. The levels of the anandamide-related mediators with anti-inflammatory or anti-lipogenic properties, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), decreased or increased only in VAT or in both tissues, respectively. Endocannabinoid- and OEA/PEA-degrading enzymes were expressed by macrophages within atherosclerotic lesions. In vitro, 2-AG and OEA-induced monocyte migration at 0.3-1microM, which corresponds to the levels observed in aortas. PEA 1microM also induced monocyte migration but counteracted the effect of 2-AG, whereas OEA enhanced it. Enhanced 2-AG levels in advanced atherosclerotic lesions may trigger the inflammatory process by recruiting more inflammatory cells and inducing extracellular matrix degradation via CB(2) receptors, and this possibility was supported in vitro but not in vivo by experiments with the CB(2) antagonist, SR144528.

    Topics: Amides; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Camphanes; Cannabinoid Receptor Modulators; Cholesterol; Endocannabinoids; Ethanolamines; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oleic Acids; Palmitic Acids; Pyrazoles; Receptor, Cannabinoid, CB2

2009